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Invited Commentary
LESS ISMORE
Guideline-Based Prescribing in Frail Elderly Patients
Jennifer Tjia, MD, MSCE; Kate Lapane, PhD
In this issue of JAMA Internal Medicine, Steinman and
colleagues1 report on their carefully designed observational
study of the comparative benefits and harms of β-blocker use
for acute myocardial infarction (AMI) in adults 85 years or
older—apopulation forwhom
no evidence from random-
izedclinical trials exists.They
found that, within 3 months
of hospital discharge after AMI, 12.1% of their study popula-
tion experienced functional decline, 25.3% were rehospital-
ized, and 14.1% died. Use of β-blockers decreased the odds of
deathregardlessof functional status.Thisshouldbegoodnews.
Guideline-basedmedications forAMIhavebeenunderused in
older adults. The study’s confirmation of the survival benefit
for frail elders will likely spur an increase in β-blocker pre-
scribing for older adults with multiple comorbidities.
However, this well-executed study reveals a more com-
plexphenomenon.Useofβ-blockers increasedtherisk for func-
tional decline among the cognitively and functionally im-
paired. Steinman et al1 report that, among elders with
functional or cognitive impairment, the number needed to
harmissimilar to thenumberneededtotreat toprevent1death.
This journal’s “Less is More“ series and the American Board
of Internal Medicine Foundation’s Choosing Wisely cam-
paignhighlight theneed tocurtail theuseofnonbeneficial and
potentially harmfulmedications, tests, and treatments. Thus,
these findings must give us pause.
Despite some individuals wanting to live forever, in real-
ity, many older adults reach the point when quality of life is
more important than extensionof life. The studyby Steinman
et al1 is important because the primary outcome was func-
tional decline and not death or hospital readmission. The au-
thors confirmed that the practice of avoiding prescription of
β-blockers in frail and highly vulnerable elders with func-
tional impairment is reasonable. Steinman et al1 extend that
knowledge 1 step further. They shed some light on where the
tippingpoint is. In thenursinghomepopulation, this point ap-
pears to be at the level of moderate cognitive impairment (ie,
havingshort-termmemory lossandamoderately impairedabil-
ity for decisionmaking or an inability tomake their needs un-
derstood) or severe functional impairment (ie, extensive as-
sistanceor totaldependence formost, ifnotall, activityofdaily
living needs, including dressing, personal hygiene, toileting,
ambulation, transferring, bedmobility, and eating). The 2014
guidelines for themanagementofnon–STelevationacutecoro-
nary syndromes fromtheAmericanHeartAssociation and the
American College of Cardiology (AHA/ACC)2 state that phar-
macotherapy should be individualized for older adults, and
managementdecisions shouldbepatient centeredandtakepa-
tient preferences/goals, comorbidities, functional and cogni-
tive status, and life expectancy into consideration. Although
not specifically addressed in the comparable AHA/ACC guide-
lines for ST elevationmyocardial infarction,3 an informeddis-
cussionofexpectedbenefits andharms is consistentwithgood
prescribing practices and can help patients and families know
what toexpect. The studybySteinmanet al1 provides some in-
formationuseful for suchdiscussions.However, this studydid
notexamine theadverseeffectsofβ-blockers that areoften im-
portant topatients, suchas fatigue, depression, dizziness, and
orthostasis.Regardlessof thecaresetting,cliniciansshouldhave
frank discussions about extending prescription of guideline-
recommended medications for AMI to patients with severe
functional limitations and moderate cognitive deficits be-
cause medication-induced harmsmay outweigh the benefit.
Amoredifficultquestion(notaddressedbythisstudy)ishow
longtheβ-blocker therapyshouldbecontinuedafterAMI.Com-
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monpractice is to continue guideline-based post-AMImedica-
tiontherapyfortherestofthepatient’s life.However,noclearevi-
denceexists regardingtheappropriatedurationof treatmentbe-
yond1year intheabsenceof leftventriculardysfunction,angina,
or dysrhythmia.4 Given that the balance between benefit and
harm of treatment accompanying an acute illness shifts in the
courseofapatient’s life,cliniciansmustalsoconsiderhowtodis-
cusswhentodiscontinue treatmentswithpatientswhomaybe
experiencing declines in physical and cognitive functioning.
Asclinicians,wemust remember that thespectrumofgood
prescribing practices spans initiation to discontinuation of
therapy.5 Initiation of therapy, in many ways, is the easy part
of the prescribing spectrum. Improving prescribing practice
for patients late in life, including the oldest-old patients (≥85
years), those with serious illness and a limited prognosis be-
cause ofmultiple chronicmedical conditions, and thosewith
multiple functional impairments may be achieved by using a
model that calls for appreciation of a patients’ prognosis (re-
maining life expectancy), medication treatment target, time
needed for medication to produce the intended benefit, and
the patient’s goals of care.6
Themore challenging part is considering discontinuation
of therapy. The barriers include uncertainty on the part of cli-
nicians about the benefits of continuing treatment, uncer-
tainty about the benefits andharmsof discontinuing therapy,
and the lackofprotocols forhowto taper therapy.Anotherma-
jor challenge is the timing of and the actual time required to
engage in shareddecisionmakingwithpatients and their fam-
ily. Clinicians generally lack training about how to have such
conversations. Scott and colleagues5 propose the following 5
essential steps required fordecisionmakingaboutdeprescrib-
ing: (1) ascertain all drugs the patient is taking and the rea-
sons for each one; (2) consider the overall risk for drug-
induced harm in individual patients; (3) assess each drug
regimen for its eligibility tobediscontinued; (4)prioritizedrug
treatments for discontinuation; and (5) implement andmoni-
tor the drug discontinuation regimen. Although this frame-
work is useful to practitioners who struggle with the process
of stopping therapy, mastering the art of the conversation to
address the beliefs, fears, and hopes of the patients and fami-
lies, who may have been told that they need to take some of
these medicines for the rest of their lives, takes practice.
Good prescribing is a balancing act that is as much an art
as a science. The present study adds to the science part. How-
ever,despite its rigorousandcareful execution, it remains level
B quality of evidence, namely, moderate quality from a well-
designed, nonrandomized, observational study. The reported
findingsaresubject to thesamelimitationsof selectionbiasand
residualconfoundingthatplagueallobservational studies.Spe-
cifically, removing the patients at highest risk for poor out-
comes (ie, thosewhodiedorwere rehospitalizedwithin 14days
of hospital discharge) likely biased the findings toward a posi-
tive survival benefit of β-blockers. A randomized clinical trial
for frail older adults with cognitive and functional impair-
ment toexamineguideline-recommendedmedications forAMI
is needed to address biases inherent in observational studies.
Furthermore, a trial for discontinuation of β-blocker therapy
in the population of elders with life-limiting illness would be
prudent given the changing benefits and risks of treatment
across levels of cognitive and functional impairment. ThePal-
liativeCareResearchCooperativeGroup’sdiscontinuation trial
for statin therapy among adults with life-limiting illness7 pro-
vides a useful model for such a study. Regardless of the state
of the science, all clinicians should consider improving their
approach to communication regarding initiating (and discon-
tinuing) therapy for those in the last quarter of their life.
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